Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though tirzepatide outperformed semaglutide for adults with limited physical function, study data revealed.

Semaglutide therapy was associated with higher likelihood of passing low-risk cardiovascular thresholds among patients with obesity.

Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per month for new self-pay patients in the United States,

Please provide your email address to receive an email when new articles are posted on . Semaglutide 7.2 mg reduced body weight vs. placebo in patients with obesity regardless of diabetes status. There were no serious safety signals, but semaglutide 7.2 mg ...

Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight loss and a modest decrease in A1c levels are seen with tirzepatide.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to the price cuts, the company could ultimately benefit more from making its drugs more accessible to patients.

Shares of Novo Nordisk fell sharply on Monday after the company announced that a high-profile trial testing whether its oral semaglutide medicine could slow the progression of Alzheimer’s disease had failed to meet its primary goal.

Novo Nordisk’s semaglutide trials fail to slow Alzheimer’s, sending shares lower. Researchers continue to explore GLP‑1 drugs for dementia treatment.

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according to a speaker.